Greywolf Therapeutics and Genomics Launch Strategic Relationship to Develop First‑in‑Class Treatments for Autoimmune Diseases
ERAPs (ERAP1 and ERAP2) are emerging therapeutic targets associated with multiple autoimmune diseases.Genomics will assemble the largest available genetic resource...
Read moreDetails